Back to Search Start Over

Engineering antigen-presenting cells for immunotherapy of autoimmunity.

Engineering antigen-presenting cells for immunotherapy of autoimmunity.

Authors :
Smith CT
Wang Z
Lewis JS
Source :
Advanced drug delivery reviews [Adv Drug Deliv Rev] 2024 Jul; Vol. 210, pp. 115329. Date of Electronic Publication: 2024 May 08.
Publication Year :
2024

Abstract

Autoimmune diseases are burdensome conditions that affect a significant fraction of the global population. The hallmark of autoimmune disease is a host's immune system being licensed to attack its tissues based on specific antigens. There are no cures for autoimmune diseases. The current clinical standard for treating autoimmune diseases is the administration of immunosuppressants, which weaken the immune system and reduce auto-inflammatory responses. However, people living with autoimmune diseases are subject to toxicity, fail to mount a sufficient immune response to protect against pathogens, and are more likely to develop infections. Therefore, there is a concerted effort to develop more effective means of targeting immunomodulatory therapies to antigen-presenting cells, which are involved in modulating the immune responses to specific antigens. In this review, we highlight approaches that are currently in development to target antigen-presenting cells and improve therapeutic outcomes in autoimmune diseases.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-8294
Volume :
210
Database :
MEDLINE
Journal :
Advanced drug delivery reviews
Publication Type :
Academic Journal
Accession number :
38729265
Full Text :
https://doi.org/10.1016/j.addr.2024.115329